DOI:

10.37988/1811-153X_2024_1_32

Resolution phase of inflammation, resolvins and periodontitis: review

Downloads

Authors

  • O.A. Neprelyuk 1, PhD in Medical Sciences, associate professor of the Prosthodontics Department
    ORCID: 0000-0002-0033-9878
  • S.I. Zhad’ko 1, PhD in Medical Sciences, full professor of the Prosthodontics Department
    ORCID: 0000-0003-1622-1011
  • O.L. Irza 1, PhD in Medical Sciences, associate professor of the Prosthodontics Department
    ORCID: 0000-0002-9579-387X
  • M.A. Kriventsov 1, PhD in Medical Sciences, associate professor and head of the Pathological anatomy Department
    ORCID: 0000-0001-5193-4311
  • 1 Crimean Federal University, 295006, Simferopol, Russia

Abstract

The literature review presents data on modern ideas about the resolving phase of inflammation and the role of resolvins as a new class of endogenous substances — derivatives of omega-3 polyunsaturated fatty acids (eicosapentaenoic acid and docosahexaenoic acid), in relation to chronic inflammation of periodontal tissues. Based on initial studies of resolvins, as well as data from in vitro and in vivo studies in experimental models of periodontitis, data are presented in a systematic way regarding the key biological effects of resolvins, as well as their impact on the course of the inflammatory response and bone resorption of the alveolar process of the jaw. Taking into account the identified effects and the main pathogenetic mechanisms involved in the development of periodontitis, data on potential key points of application of resolvins on the course of periodontitis are systematized, as well as promising areas for further research are identified.

Key words:

inflammation, resolution, resolvins, periodontitis, experimental studies

For Citation

[1]
Neprelyuk O.A., Zhad’ko S.I., Irza O.L., Kriventsov M.A. Resolution phase of inflammation, resolvins and periodontitis: review. Clinical Dentistry (Russia).  2024; 27 (1): 32—39. DOI: 10.37988/1811-153X_2024_1_32

References

  1. Avula H., Chakravarthy Y. Models of periodontal disease pathogenesis: A journey through time. J Indian Soc Periodontol. 2022; 26 (3): 204—212. PMID: 35602539
  2. Cekici A., Kantarci A., Hasturk H., Van Dyke T.E. Inflammatory and immune pathways in the pathogenesis of periodontal disease. Periodontol 2000. 2014; 64 (1): 57—80. PMID: 24320956
  3. Van Dyke T.E., Sima C. Understanding resolution of inflammation in periodontal diseases: Is chronic inflammatory periodontitis a failure to resolve? — Periodontol 2000. 2020; 82 (1): 205—213. PMID: 31850636
  4. Sugimoto M.A., Sousa L.P., Pinho V., Perretti M., Teixeira M.M. Resolution of inflammation: What controls its onset? — Front Immunol. 2016; 7: 160. PMID: 27199985
  5. Serhan C.N., Brain S.D., Buckley C.D., Gilroy D.W., Haslett C., O’Neill L.A., Perretti M., Rossi A.G., Wallace J.L. Resolution of inflammation: state of the art, definitions and terms. FASEB J. 2007; 21 (2): 325—32. PMID: 17267386
  6. Serhan C.N. Discovery of specialized pro-resolving mediators marks the dawn of resolution physiology and pharmacology. Mol Aspects Med. 2017; 58: 1—11. PMID: 28263773
  7. Serhan C.N., Clish C.B., Brannon J., Colgan S.P., Chiang N., Gronert K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med. 2000; 192 (8): 1197—204. PMID: 11034610
  8. Serhan C.N., Hong S., Gronert K., Colgan S.P., Devchand P.R., Mirick G., Moussignac R.L. Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits initiated by aspirin treatment that counter proinflammation signals. J Exp Med. 2002; 196 (8): 1025—37. PMID: 12391014
  9. Dalli J., Colas R.A., Serhan C.N. Novel n-3 immunoresolvents: structures and actions. Sci Rep. 2013; 3: 1940. PMID: 23736886
  10. Serhan C.N., Libreros S., Nshimiyimana R. E-series resolvin metabolome, biosynthesis and critical role of stereochemistry of specialized pro-resolving mediators (SPMs) in inflammation-resolution: Preparing SPMs for long COVID-19, human clinical trials, and targeted precision nutrition. Semin Immunol. 2022; 59: 101597. PMID: 35227568
  11. Arnardottir H., Thul S., Pawelzik S.C., Karadimou G., Artiach G., Gallina A.L., Mysdotter V., Carracedo M., Tarnawski L., Caravaca A.S., Baumgartner R., Ketelhuth D.F., Olofsson P.S., Paulsson-Berne G., Hansson G.K., Bäck M. The resolvin D1 receptor GPR32 transduces inflammation resolution and atheroprotection. J Clin Invest. 2021; 131 (24): e142883. PMID: 34699386
  12. Chiang N., Sakuma M., Rodriguez A.R., Spur B.W., Irimia D., Serhan C.N. Resolvin T-series reduce neutrophil extracellular traps. Blood. 2022; 139 (8): 1222—1233. PMID: 34814186
  13. Krishnamoorthy S., Recchiuti A., Chiang N., Fredman G., Serhan C.N. Resolvin D1 receptor stereoselectivity and regulation of inflammation and proresolving microRNAs. Am J Pathol. 2012; 180 (5): 2018—27. PMID: 22449948
  14. Lee S.H., Tonello R., Im S.T., Jeon H., Park J., Ford Z., Davidson S., Kim Y.H., Park C.K., Berta T. Resolvin D3 controls mouse and human TRPV1-positive neurons and preclinical progression of psoriasis. Theranostics. 2020; 10 (26): 12111—12126. PMID: 33204332
  15. Oh S.F., Dona M., Fredman G., Krishnamoorthy S., Irimia D., Serhan C.N. Resolvin E2 formation and impact in inflammation resolution. J Immunol. 2012; 188 (9): 4527—34. PMID: 22450811
  16. Dona M., Fredman G., Schwab J.M., Chiang N., Arita M., Goodarzi A., Cheng G., von Andrian U.H., Serhan C.N. Resolvin E1, an EPA-derived mediator in whole blood, selectively counterregulates leukocytes and platelets. Blood. 2008; 112 (3): 848—55. PMID: 18480426
  17. Ohira T., Arita M., Omori K., Recchiuti A., Van Dyke T.E., Serhan C.N. Resolvin E1 receptor activation signals phosphorylation and phagocytosis. J Biol Chem. 2010; 285 (5): 3451—61. PMID: 19906641
  18. Codagnone M., Cianci E., Lamolinara A., Mari V.C., Nespoli A., Isopi E., Mattoscio D., Arita M., Bragonzi A., Iezzi M., Romano M., Recchiuti A. Resolvin D1 enhances the resolution of lung inflammation caused by long-term Pseudomonas aeruginosa infection. Mucosal Immunol. 2018; 11 (1): 35—49. PMID: 28422188
  19. Spite M., Norling L.V., Summers L., Yang R., Cooper D., Petasis N.A., Flower R.J., Perretti M., Serhan C.N. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature. 2009; 461 (7268): 1287—91. PMID: 19865173
  20. Takamiya R., Fukunaga K., Arita M., Miyata J., Seki H., Minematsu N., Suematsu M., Asano K. Resolvin E1 maintains macrophage function under cigarette smoke-induced oxidative stress. FEBS Open Bio. 2012; 2: 328—33. PMID: 23772366
  21. López-Vicario C., Rius B., Alcaraz-Quiles J., García-Alonso V., Lopategi A., Titos E., Clària J. Pro-resolving mediators produced from EPA and DHA: Overview of the pathways involved and their mechanisms in metabolic syndrome and related liver diseases. Eur J Pharmacol. 2016; 785: 133—143. PMID: 25987424
  22. Werz O., Gerstmeier J., Libreros S., De la Rosa X., Werner M., Norris P.C., Chiang N., Serhan C.N. Human macrophages differentially produce specific resolvin or leukotriene signals that depend on bacterial pathogenicity. Nat Commun. 2018; 9 (1): 59. PMID: 29302056
  23. Dalli J., Winkler J.W., Colas R.A., Arnardottir H., Cheng C.Y., Chiang N., Petasis N.A., Serhan C.N. Resolvin D3 and aspirin-triggered resolvin D3 are potent immunoresolvents. Chem Biol. 2013; 20 (2): 188—201. PMID: 23438748
  24. Kim N., Ramon S., Thatcher T.H., Woeller C.F., Sime P.J., Phipps R.P. Specialized proresolving mediators (SPMs) inhibit human B-cell IgE production. Eur J Immunol. 2016; 46 (1): 81—91. PMID: 26474728
  25. Cheng T., Ding S., Liu S., Li X., Tang X., Sun L. Resolvin D1 improves the Treg/Th17 imbalance in systemic lupus erythematosus through miR-30e-5p. Front Immunol. 2021; 12: 668760. PMID: 34093566
  26. Mizraji G., Heyman O., Van Dyke T.E., Wilensky A. Resolvin D2 restrains Th1 immunity and prevents alveolar bone loss in murine periodontitis. Front Immunol. 2018; 9: 785. PMID: 29922275
  27. Yamada H., Saegusa J., Sendo S., Ueda Y., Okano T., Shinohara M., Morinobu A. Effect of resolvin D5 on T cell differentiation and osteoclastogenesis analyzed by lipid mediator profiling in the experimental arthritis. Sci Rep. 2021; 11 (1): 17312. PMID: 34453072
  28. Chattopadhyay R., Mani A.M., Singh N.K., Rao G.N. Resolvin D1 blocks H2O2-mediated inhibitory crosstalk between SHP2 and PP2A and suppresses endothelial-monocyte interactions. Free Radic Biol Med. 2018; 117: 119—131. PMID: 29408202
  29. Díaz Del Campo L.S., García-Redondo A.B., et al. Resolvin D2 attenuates cardiovascular damage in angiotensin II-induced hypertension. Hypertension. 2023; 80 (1): 84—96. PMID: 36337053
  30. Shamoon L., Espitia-Corredor J.A., Dongil P., Menéndez-Ribes M., Romero A., Valencia I., Díaz-Araya G., Sánchez-Ferrer C.F., Peiró C. Resolvin E1 attenuates doxorubicin-induced endothelial senescence by modulating NLRP3 inflammasome activation. Biochem Pharmacol. 2022; 201: 115078. PMID: 35551917
  31. Qu X., Zhang X., Yao J., Song J., Nikolic-Paterson D.J., Li J. Resolvins E1 and D1 inhibit interstitial fibrosis in the obstructed kidney via inhibition of local fibroblast proliferation. J Pathol. 2012; 228 (4): 506—19. PMID: 22610993
  32. Xu H., Chen J., Ge J., Xia K., Tao S., Su Y., Zhang Q. Resolvin E1 ameliorates pulpitis by suppressing dental pulp fibroblast activation in a chemerin receptor 23-dependent manner. J Endod. 2019; 45 (9): 1126—1134.e1. PMID: 31353056
  33. Zarrough A.E., Hasturk H., Stephens D.N., Van Dyke T.E., Kantarci A. Resolvin D1 modulates periodontal ligament fibroblast function. J Periodontol. 2023; 94 (5): 683—693. PMID: 36416879
  34. Albuquerque-Souza E., Schulte F., et al. Maresin-1 and resolvin E1 promote regenerative properties of periodontal ligament stem cells under inflammatory conditions. Front Immunol. 2020; 11: 585530. PMID: 33101318
  35. Khaled M., Shibani N.A., et al. Effects of resolvin D1 on cell survival and cytokine expression of human gingival fibroblasts. J Periodontol. 2013; 84 (12): 1838—46. PMID: 23398023
  36. Maekawa T., Hosur K., et al. Antagonistic effects of IL-17 and D-resolvins on endothelial Del-1 expression through a GSK-3β-C/EBPβ pathway. Nat Commun. 2015; 6: 8272. PMID: 26374165
  37. Fredman G., Oh S.F., et al. Impaired phagocytosis in localized aggressive periodontitis: rescue by resolvin E1. PLoS One. 2011; 6 (9): e24422. PMID: 21935407
  38. Hasturk H., Kantarci A., et al. RvE1 protects from local inflammation and osteoclast- mediated bone destruction in periodontitis. FASEB J. 2006; 20 (2): 401—3. PMID: 16373400
  39. Damgaard C., Kantarci A., et al. Porphyromonas gingivalis-induced production of reactive oxygen species, tumor necrosis factor-α, interleukin-6, CXCL8 and CCL2 by neutrophils from localized aggressive periodontitis and healthy donors: modulating actions of red blood cells and resolvin E1. J Periodontal Res. 2017; 52 (2): 246—254. PMID: 27146665
  40. Herrera B.S., Ohira T., et al. An endogenous regulator of inflammation, resolvin E1, modulates osteoclast differentiation and bone resorption. Br J Pharmacol. 2008; 155 (8): 1214—23. PMID: 18806821
  41. Ozaki Y., Morozumi T., et al. Inhibitory effect of omega-3 fatty acids on alveolar bone resorption and osteoclast differentiation. J Oral Sci. 2020; 62 (3): 298—302. PMID: 32581177
  42. Balta M.G., Schreurs O., et al. RvD1 (n-3 DPA) downregulates the transcription of pro-inflammatory genes in oral epithelial cells and reverses nuclear translocation of transcription factor p65 after TNF-α stimulation. Int J Mol Sci. 2022; 23 (23): 14878. PMID: 36499208
  43. Morita M., Wu S., Kobayashi Y. Stereocontrolled synthesis of resolvin D1. Org Biomol Chem. 2019; 17 (8): 2212—2222. PMID: 30720822
  44. Urbitsch F., Elbert B.L., Llaveria J., Streatfeild P.E., Anderson E.A. A modular, enantioselective synthesis of resolvins D3, E1, and hybrids. Org Lett. 2020; 22 (4): 1510—1515. PMID: 32031820
  45. Hasturk H., Kantarci A., et al. Resolvin E1 regulates inflammation at the cellular and tissue level and restores tissue homeostasis in vivo. J Immunol. 2007; 179 (10): 7021—9. PMID: 17982093
  46. Hasturk H., Abdallah R., et al. Resolvin E1 (RvE1) attenuates atherosclerotic plaque formation in diet and inflammation-induced atherogenesis. Arterioscler Thromb Vasc Biol. 2015; 35 (5): 1123—33. PMID: 25792445
  47. Lee C.T., Teles R., et al. Resolvin E1 reverses experimental periodontitis and dysbiosis. J Immunol. 2016; 197 (7): 2796—806. PMID: 27543615
  48. Alvarez C., Abdalla H., et al. RvE1 impacts the gingival inflammatory infiltrate by inhibiting the T cell response in experimental periodontitis. Front Immunol. 2021; 12: 664756. PMID: 34012448
  49. Abdullatif F.A., Almaarik B., Al-Askar M. Resolvin E1’s antimicrobial potential against Aggregatibacter actinomycetemcomitans. Front Oral Health. 2022; 3: 875047. PMID: 35571980
  50. Souto G.R., Queiroz-Junior C.M., de Abreu M.H., Costa F.O., Mesquita R.A. Pro-inflammatory, Th1, Th2, Th17 cytokines and dendritic cells: a cross-sectional study in chronic periodontitis. PLoS One. 2014; 9 (3): e91636. PMID: 24670840
  51. Chen X.T., Chen L.L., Tan J.Y., Shi D.H., Ke T., Lei L.H. Th17 and Th1 lymphocytes are correlated with chronic periodontitis. Immunol Invest. 2016; 45 (3): 243—54. PMID: 27019379

Downloads

Received

July 6, 2023

Accepted

December 21, 2023

Published on

March 21, 2024